Previous Article | Next Article ![]()
Journal of Virology, October 2001, p. 9210-9228, Vol. 75, No. 19
Harvard School of Public
Health1 and Harvard Medical
School,4 Boston, Massachusetts; National
Health Laboratory/National Blood Transfusion
Center2 and Botswana-Harvard Partnership
for HIV Research and Education,3 Gaborone,
Botswana; and Theoretical Biology and Biophysics, Group
T-10, Los Alamos National Laboratory, Los Alamos, New
Mexico5
Received 10 May 2001/Accepted 25 June 2001
The most severe human immunodeficiency virus type 1 (HIV-1)
epidemic is occurring in southern Africa. It is caused by HIV-1 subtype
C (HIV-1C). In this study we present the identification and analysis of
cumulative cytotoxic T-lymphocyte (CTL) responses in the southern
African country of Botswana. CTLs were shown to be an important
component of the immune response to control HIV-1 infection. The
definition of optimal and dominant epitopes across the HIV-1C genome
that are targeted by CTL is critical for vaccine design. The
characteristics of the predominant virus that causes the HIV-1 epidemic
in a certain geographic area and also the genetic background of the
population, through the distribution of common HLA class I alleles,
might impact dominant CTL responses in the vaccinee and in the general
population. The enzyme-linked immunospot (Elispot) gamma interferon
assay has recently been shown to be a reliable tool to map optimal CTL
epitopes, correlating well with other methods, such as intracellular
staining, tetramer staining, and the classical chromium release assay.
Using Elispot with overlapping synthetic peptides across Gag, Tat, Rev,
and Nef, we analyzed HIV-1C-specific CTL responses of HIV-1-infected
blood donors. Profiles of cumulative Elispot-based CTL responses
combined with diversity and sequence consensus data provide an
additional characterization of immunodominant regions across the HIV-1C
genome. Results of the study suggest that the construction of a
poly-epitope subtype-specific HIV-1 vaccine that includes multiple
copies of immunodominant CTL epitopes across the viral genome, derived
from predominant HIV-1 viruses, might be a logical approach to the
design of a vaccine against AIDS.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.19.9210-9228.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification of Human Immunodeficiency Virus Type 1 Subtype
C Gag-, Tat-, Rev-, and Nef-Specific Elispot-Based Cytotoxic
T-Lymphocyte Responses for AIDS Vaccine Design
*
Corresponding author. Mailing address: Department of
Immunology and Infectious Diseases, Harvard School of Public Health, FXB-402, 651 Huntington Ave., Boston, MA 02115. Phone: (617) 432-0975. Fax: (617) 739-8348. E-mail:
messex{at}hsph.harvard.edu.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|